Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
NCT ID NCT07556484
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This early study tests whether a liquid form of the drug avacopan can be safely given through a feeding tube to critically ill patients with ANCA vasculitis who have severe lung bleeding and need a ventilator. The main goal is to measure how the drug levels change in the blood over 72 hours. Only 6 participants will be enrolled at Mayo Clinic.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- avacopan (Tavneos)
- What this could lead to
- If it works, this could point toward a way to give avacopan to very sick patients who cannot swallow pills, potentially helping control severe lung inflammation.
- What could go wrong
- This is a tiny, early-phase study with only 6 participants, so results may not apply broadly. The drug is given in an experimental liquid form, and its safety and effectiveness in this setting are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diabetes drug shield kidneys from autoimmune attack?
- New study aims to detect lung damage earlier in young transplant patients
- Promising vasculitis drug trial halted early
- Hydroxychloroquine trial for rare vasculitis halted early
- New hope for Wegener's patients: drug aims to stop flare-ups
- New hope for rare vasculitis: Three-Drug trial targets Non-Responders